UA99309C2 - Замещенные пиперидинодигидротиенопиримидины - Google Patents

Замещенные пиперидинодигидротиенопиримидины

Info

Publication number
UA99309C2
UA99309C2 UAA201005780A UAA201005780A UA99309C2 UA 99309 C2 UA99309 C2 UA 99309C2 UA A201005780 A UAA201005780 A UA A201005780A UA A201005780 A UAA201005780 A UA A201005780A UA 99309 C2 UA99309 C2 UA 99309C2
Authority
UA
Ukraine
Prior art keywords
diseases
dihydrothienopyrimidines
piperidinodihydrothienopyrimidines
novel
relates
Prior art date
Application number
UAA201005780A
Other languages
English (en)
Ukrainian (uk)
Inventor
Паскаль Пузе
Ральф Андерскевітц
Хорст Доллінгер
Денніс Фіген
Томас Фокс
Рольф Гьоггель
Крістоф Хьонке
Домнік Мартірес
Петер Ніколаус
Клаус Кліндер
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99309(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA99309C2 publication Critical patent/UA99309C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны новые пиперидинодигидротиенопиримидины формулы (1) (1), в которой X означает SO или SO2, преимущественно SO, a R1, R2, R3 и R4 могут иметь указанные в п. 1 формулы изобретения значения, а также их фармакологически приемлемые соли и фармацевтические композиции, которые содержат такие соединения. Эти новые пиперидинодигидротиенопиримидины пригодны для лечения недомоганий, обусловленных нарушением функции дыхательных путей или желудочно-кишечного тракта, заболеваний дыхательных путей или желудочно-кишечного тракта, воспалительных заболеваний суставов, кожи или глаз, заболеваний периферической или центральной нервной системы или онкологических заболеваний.
UAA201005780A 2007-10-19 2008-10-16 Замещенные пиперидинодигидротиенопиримидины UA99309C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118901 2007-10-19

Publications (1)

Publication Number Publication Date
UA99309C2 true UA99309C2 (ru) 2012-08-10

Family

ID=39154006

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201005780A UA99309C2 (ru) 2007-10-19 2008-10-16 Замещенные пиперидинодигидротиенопиримидины

Country Status (34)

Country Link
US (1) US8754073B2 (ru)
EP (3) EP2215092B1 (ru)
JP (2) JP5150728B2 (ru)
KR (1) KR101548975B1 (ru)
CN (2) CN101827852B (ru)
AR (1) AR069075A1 (ru)
AT (1) ATE542825T1 (ru)
AU (1) AU2008313660B2 (ru)
BR (1) BRPI0818006B8 (ru)
CA (1) CA2705414C (ru)
CL (1) CL2008003096A1 (ru)
CY (2) CY1112703T1 (ru)
DK (2) DK2215092T3 (ru)
EA (1) EA019480B1 (ru)
EC (1) ECSP10010156A (ru)
ES (2) ES2381452T3 (ru)
HK (1) HK1145677A1 (ru)
HR (2) HRP20120334T1 (ru)
MA (1) MA31845B1 (ru)
ME (1) ME01330B (ru)
MX (1) MX2010004026A (ru)
MY (1) MY153979A (ru)
NZ (1) NZ585346A (ru)
PE (2) PE20091386A1 (ru)
PL (2) PL2215092T3 (ru)
PT (2) PT2215092E (ru)
RS (1) RS52271B (ru)
SI (2) SI2610258T1 (ru)
TN (1) TN2010000175A1 (ru)
TW (1) TWI421077B (ru)
UA (1) UA99309C2 (ru)
UY (1) UY31405A1 (ru)
WO (1) WO2009050248A1 (ru)
ZA (1) ZA201001683B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
BRPI0818671A2 (pt) 2007-10-18 2015-09-15 Boehringer Ingelheim Int preparação de diidrotieno[3,2-d]pirimidinas e intermediários empregados nela
BRPI0818006B8 (pt) * 2007-10-19 2021-05-25 Boehringer Ingelheim Int compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CA2753604A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
WO2011124524A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
JP2013523792A (ja) 2010-04-08 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ
WO2011143057A1 (en) * 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
BR112015018355A8 (pt) 2013-02-04 2018-01-23 Gruenenthal Gmbh novos compostos de pirimidina condensados substituídos
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN104892720B (zh) * 2014-03-07 2016-10-26 华东师范大学 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
AU2017288755B9 (en) * 2016-06-30 2021-08-19 Japanese Foundation For Cancer Research Novel compound or pharmaceutically acceptable salt thereof
JP7216719B2 (ja) * 2017-09-20 2023-02-01 ユニオン・セラピューティクス・アクティエセルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
AU2018357775B2 (en) 2017-10-23 2024-02-15 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
EP3724195B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
JP7198820B2 (ja) * 2017-12-15 2023-01-04 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP7203846B2 (ja) * 2017-12-15 2023-01-13 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
WO2020048827A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2023104958A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
WO2023104961A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2023232135A1 (zh) * 2022-06-02 2023-12-07 西藏海思科制药有限公司 Pde4b抑制剂及其用途
WO2023241684A1 (zh) * 2022-06-16 2023-12-21 武汉人福创新药物研发中心有限公司 Pde4b抑制剂
CN115040503B (zh) * 2022-07-26 2023-10-10 云南民族大学 螺环二烯酮型木脂素类化合物在制药中的应用
WO2024032673A1 (zh) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Pde4b抑制剂及其用途
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
WO2024067660A1 (zh) * 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (ru) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (ru) 1965-03-31
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (ru) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
TR200402579T4 (tr) 2000-10-12 2004-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristalin monohidrat, bunun imalat yöntemi ve bir ilaç maddesinin imalatında kullanımı
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
JP2005503345A (ja) 2001-04-30 2005-02-03 バイエル・コーポレーシヨン 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SI1401445T1 (sl) 2001-06-22 2007-02-28 Boehringer Ingelheim Pharma Kristalinicen antiholinergik, postopek za njegovo pripravo in njegova uporaba za pripravo zdravila
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
WO2004096810A1 (en) 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
WO2004104179A2 (en) 2003-05-16 2004-12-02 Wisconsin Alumni Research Foundation Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
CA2801065C (en) 2003-10-02 2020-04-28 Dsm Ip Assets B.V. Production of high levels of dha in microalgae using modified amounts of chloride and potassium
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
US7834010B2 (en) 2003-12-23 2010-11-16 Serodus As Modulators of peripheral 5-HT receptors
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CN101171005A (zh) 2005-05-11 2008-04-30 尼科梅德有限责任公司 Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合
PT1874781E (pt) * 2006-04-19 2009-07-27 Boehringer Ingelheim Int Di-hidro-tienopirimidinas para o tratamento de doenças inflamatórias
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
AU2008240764C1 (en) 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
BRPI0818671A2 (pt) 2007-10-18 2015-09-15 Boehringer Ingelheim Int preparação de diidrotieno[3,2-d]pirimidinas e intermediários empregados nela
TW200934785A (en) 2007-10-19 2009-08-16 Schering Corp Compounds for inhibiting KSP kinesin activity
JP2011500621A (ja) 2007-10-19 2011-01-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
BRPI0818006B8 (pt) 2007-10-19 2021-05-25 Boehringer Ingelheim Int compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
AR068921A1 (es) 2007-10-19 2009-12-16 Astrazeneca Ab Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
US8592400B2 (en) 2009-02-27 2013-11-26 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753604A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
AR069075A1 (es) 2009-12-30
TWI421077B (zh) 2014-01-01
CN101827852A (zh) 2010-09-08
ATE542825T1 (de) 2012-02-15
SI2610258T1 (sl) 2014-12-31
EA201000609A1 (ru) 2010-10-29
PE20131463A1 (es) 2013-12-23
BRPI0818006A2 (pt) 2015-12-22
MX2010004026A (es) 2010-04-30
RS52271B (en) 2012-10-31
SI2215092T1 (sl) 2012-04-30
ES2524910T3 (es) 2014-12-15
EP2610258A1 (de) 2013-07-03
EP2215092A1 (de) 2010-08-11
US20110021501A1 (en) 2011-01-27
TW200918074A (en) 2009-05-01
JP2011500640A (ja) 2011-01-06
HK1145677A1 (en) 2011-04-29
CN101827852B (zh) 2014-07-30
EP2380891B1 (de) 2013-12-11
ECSP10010156A (es) 2010-06-29
JP5150728B2 (ja) 2013-02-27
JP5615889B2 (ja) 2014-10-29
TN2010000175A1 (fr) 2011-11-11
CY1112703T1 (el) 2016-02-10
EA019480B1 (ru) 2014-04-30
JP2013064001A (ja) 2013-04-11
ZA201001683B (en) 2010-10-27
KR101548975B1 (ko) 2015-09-01
EP2215092B1 (de) 2012-01-25
KR20100100807A (ko) 2010-09-15
CA2705414C (en) 2016-05-24
MA31845B1 (fr) 2010-11-01
CL2008003096A1 (es) 2010-02-12
CY1115858T1 (el) 2017-01-25
EP2610258B1 (de) 2014-08-27
PL2215092T3 (pl) 2012-07-31
US8754073B2 (en) 2014-06-17
PT2610258E (pt) 2014-10-24
UY31405A1 (es) 2009-05-29
DK2215092T3 (da) 2012-05-07
BRPI0818006B1 (pt) 2019-10-22
PE20091386A1 (es) 2009-10-17
EP2380891A1 (de) 2011-10-26
CN104069112A (zh) 2014-10-01
AU2008313660B2 (en) 2013-11-07
PL2610258T3 (pl) 2015-02-27
BRPI0818006B8 (pt) 2021-05-25
ES2381452T3 (es) 2012-05-28
CA2705414A1 (en) 2009-04-23
PT2215092E (pt) 2012-04-10
AU2008313660A1 (en) 2009-04-23
HRP20141153T1 (hr) 2015-02-13
NZ585346A (en) 2011-09-30
HRP20120334T1 (hr) 2012-05-31
DK2610258T3 (da) 2014-11-10
ME01330B (me) 2013-12-20
MY153979A (en) 2015-04-30
WO2009050248A1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MX2008012915A (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias.
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
EA200901373A1 (ru) Аминогетероциклические соединения
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
MX2009014001A (es) Derivados de isoxazol-imidazol.
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
GEP20125438B (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
TW200724143A (en) Novel compounds for the treatment of inflammatory diseases
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
UA97944C2 (ru) Соединения для лечения воспалительных заболеваний
TH104495B (th) ซับสทิทิวเทด พิเพอริดิโน-ไดไฮโดรไธเอโนพิริมิดีน